Firebrick Pharma (ASX:FRE) intends to get its Nasodine nasal spray approved in all markets over the long term to receive royalties and license fees through its partners, according to a Wednesday filing with the Australian bourse.
In its investor update, Firebrick Pharma said it expects a decision on its application for Nasodine to be marketed as a nasal antiseptic in Europe in 2025. Once approved, the company plans to lodge its application in New Zealand and South Africa.
Nasodine is being marketed as a nasal cleanser in the US, where the company plans to pursue pharmacy distribution.
In the Philippines, the product is expected to be launched as a nasal antiseptic in 2025.
The pharmaceutical company's shares were up nearly 8% in recent Wednesday trade.
Price (AUD): $0.06, Change: $+0.004, Percent Change: +7.69%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。